Tabakentwöhnung bei COPD - S3 Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin

Inhalt Seite 1. Einleitung 255 2. Evidenzdarlegung der Leitlinie Tabakentwöhnung bei COPD 256 3. Erstellungsprozess 256 4. Epidemiologie des Zigarettenrauchens 256 5. Tabakkonsum und Tabakabhängigkeit 256 6. Tabakrauchen verursacht eine Vielzahl von Lungenerkrankungen 257 7. Tabakrauchen als Ursache der COPD 258 8. Passivrauchen als Ursache der COPD 259 9. Tabakrauchen bei Patienten mit COPD 259 10. Anamnese 259 11. Diagnostik/Fragebogen 260 12. Motivierende Beratung 261 13. Effekte der Tabakentwöhnung 262 14. Rauchreduktion ist keine Alternative zum Rauchstopp 262 15. Integrierter Ansatz, Tabakentwöhnungsprogramm 263 16. Tabakentwöhnung in ambulanten und stationären Strukturen 263 17. Medikamentöse Behandlung 264 18. Prävention und gesundheitsökonomische Aspekte 265 19. Qualitätsindikatoren 266 20. Anhang 266 21. Literatur 267

Literatur

• 1 Bloch R E, Lauterbach K, Oesingmann U. et al . Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997.  Deutsches Ärzteblatt. 1997;  94 A2154/B-1831/C-1635
• 2 Phillips B, Ball C, Sackett D. Levels of evidence, http://www.cebm.net/index.aspx?o = 1025.  Oxford. Centre for Evidence-based Medicine 2001
• 3 Abholz H H, Gillissen A, Magnussen H. et al .Nationale VersorgungsLeitlinie COPD, Langfassung, Version 1.2. In: Bundesärztekammer (BÄK) Arbeitsgemeinschaft der Deutschen Ärztekammern, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) 2006
• 4 Forsyth L, Graham K, Harbour R T. et al .SIGN 50: A guideline developers' handbook. Edinburgh: Scottish Intercollegiate Guidlines Network 2004
• 5 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV) .Nationales Programm für Versorgungs-Leitlinien. Methoden-Report 2004
• 6 Tonnesen P, Carrozzi L, Fagerstrom K O. et al . Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy.  Eur Respir J. 2007;  29 390-417
• 7 Vogelmeier C, Buhl R, Criée C P. et al . Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin.  Pneumologie. 2007;  61 1-40
• 8 Pauwels R A, Buist A S, Calverley P M. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.  Am J Respir Crit Care Med. 2001;  163 1256-1276
• 9 Rabe K F, Hurd S, Anzueto A. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.  Am J Respir Crit Care Med. 2007;  176 532-555
• 10 Aigner K, Homeier I, Koessler W. et al . Standards der Raucherentwöhnung, Konsensus der ÖGP.  Wiener Klinische Wochenschrift. 2005;  117 Supplement 2 1-22
• 11 National Health Committee .Guidelines for Smoking Cessation.  Wellington, New Zealand 2004
• 12 National Collaborating Centre for Chronic Conditions, (NICE) . Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care.  Thorax. 2004;  59 1-232
• 13 West R, McNeill A, Raw M. Smoking Cessation Guidelines for Scotland: 2004 Update. In: NHS Health Scotland and ASH Scotland 2004
• 14 Batra A, Lindinger P, Schütz C. Tabakbedingte Störungen „Leitlinie Tabakentwöhnung”. In: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften 2004
• 15 Anderson J E, Jorenby D E, Scott W J. et al . Treating Tobacco Use and Dependence: An Evidence-Based Clinical Practice Guideline for Tobacco Cessation.  Chest. 2002;  121 932-941
• 16 Orsetti K. Smoking Cessation Guideline. In: University of Michigan Health System 2001
• 17 Bundesärztekammer, Kassenärztliche Bundesvereinigung . Checkliste Methodische Qualität von Leitlinien, 2. Version (8/1999).  Deutsches Ärzteblatt. 2000;  97 A1170
• 18 Parrott S, Godfrey C. Economics of smoking cessation.  Bmj. 2004;  328 947-949
• 19 Fiore M C. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline.  Respir Care. 2000;  45 1196-1199
• 20 U.S. Department of Health and Human Services .Reducing Tobacco Use: A Report of the Surgeon General.  Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2000
• 21 Rosser W, Tremblay M. Smoking Cessation Guidelines. In: Pegasus Healthcare International 2000
• 22 West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority.  Thorax. 2000;  55 987-999
• 23 Parrott S, Godfrey C, Raw M. et al . Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority.  Thorax. 1998;  53 Suppl 5 S1-38
• 24 Raw M, McNeill A, West R. Smoking Cessation Guidelines for Health Professionals - A guide to effective smoking cessation interventions for the health care system.  Thorax. 1998;  53 1-18
• 25 Arzneimittelkommission der deutschen Ärzteschaft . Empfehlungen zur Therapie der Tabakabhängigkeit.  Suchtmed. 2001;  3 156-175
• 26 Hoch E, Mühlig S, Nowak D. et al .Rauchen und Nikotinabhängigkeit in Deutschland: Eine klinisch-epidemiologische Perspektive. Zeitschrift für klinische Psychologie und Psychotherapie (in press)
• 27 Lampert T, Burger M. Verbreitung und Strukturen des Tabakkonsums in Deutschland.  Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz. 2005;  48 1231-1241
• 28 Janson C, Kunzli N, de Marco R. et al . Changes in active and passive smoking in the European Community Respiratory Health Survey.  Eur Respir J. 2006;  27 517-524
• 29 Miller C H, Burgoon M, Grandpre J R. et al . Identifying principal risk factors for the initiation of adolescent smoking behaviors: the significance of psychological reactance.  Health Commun. 2006;  19 241-252
• 30 Schumann A, Hapke U, Meyer C. et al . Prevalence, characteristics, associated mental disorders and predictors of DSM-IV nicotine dependence.  Eur Addict Res. 2004;  10 29-34
• 31 Rounsaville B J, Bryant K, Babor T. et al . Cross system agreement for substance use disorders: DSM-III-R, DSM-IV and ICD-10.  Addiction. 1993;  88 337-348
• 32 Watkins S S, Koob G F, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal.  Nicotine Tob Res. 2000;  2 19-37
• 33 Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.  Proc Natl Acad Sci U S A. 1988;  85 5274-5278
• 34 Balfour D J. Neural mechanisms underlying nicotine dependence.  Addiction. 1994;  89 1419-1423
• 35 Dani J A, Heinemann S. Molecular and cellular aspects of nicotine abuse.  Neuron. 1996;  16 905-908
• 36 Corrigall W A, Franklin K B, Coen K M. et al . The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.  Psychopharmacology (Berl). 1992;  107 285-289
• 37 Nelson C B, Wittchen H U. Smoking and nicotine dependence. Results from a sample of 14- to 24-year-olds in Germany.  Eur Addict Res. 1998;  4 42-49
• 38 Centers for Disease Control and Prevention (CDC) . Cigarette smoking among adults - United States, 1995.  MMWR Morb Mortal Wkly Rep. 1997;  46 1217-1220
• 39 West R, Sohal T. “Catastrophic” pathways to smoking cessation: findings from national survey.  Bmj. 2006;  332 458-460
• 40 Hughes J R, Hatsukami D. Signs and symptoms of tobacco withdrawal.  Arch Gen Psychiatry. 1986;  43 289-294
• 41 Le Foll B, Goldberg S R. Nicotine as a typical drug of abuse in experimental animals and humans.  Psychopharmacology (Berl). 2006;  184 367-381
• 42 Malin D H, Lake J R, Carter V A. et al . Naloxone precipitates nicotine abstinence syndrome in the rat.  Psychopharmacology (Berl). 1993;  112 339-342
• 43 Epping-Jordan M P, Watkins S S, Koob G F. et al . Dramatic decreases in brain reward function during nicotine withdrawal.  Nature. 1998;  393 76-79
• 44 Benwell M E, Balfour D J, Anderson J M. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.  J Neurochem. 1988;  50 1243-1247
• 45 Breese C R, Marks M J, Logel J. et al . Effect of smoking history on [3H]nicotine binding in human postmortem brain.  J Pharmacol Exp Ther. 1997;  282 7-13
• 46 Perry D C, Davila-Garcia M I, Stockmeier C A. et al . Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies.  J Pharmacol Exp Ther. 1999;  289 1545-1552
• 47 Benwell M E, Balfour D J. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles.  Psychopharmacology (Berl). 1979;  63 7-11
• 48 Benwell M E, Balfour D J. The effects of nicotine administration on 5-HT uptake and biosynthesis in rat brain.  Eur J Pharmacol. 1982;  84 71-77
• 49 Fidler J A, Wardle J, Brodersen N H. et al . Vulnerability to smoking after trying a single cigarette can lie dormant for three years or more.  Tob Control. 2006;  15 205-209
• 50 Church D F, Pryor W A. Free-radical chemistry of cigarette smoke and its toxicological implications.  Environ Health Perspect. 1985;  64 111-126
• 51 Church D F, Pryor W A. The oxidative stress placed on the lung by cigarette smoke. In: Crystal RG, West JB (eds). The Lung NY: Raven Press 1991: 1975-1979
• 52 MacNee W, Wiggs B, Belzberg A S. et al . The effect of cigarette smoking on neutrophil kinetics in human lungs.  N Engl J Med. 1989;  321 924-928
• 53 Nadel J A. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies.  Chest. 2000;  117 386S-389S
• 54 Walsh D E, Greene C M, Carroll T P. et al . Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium.  J Biol Chem. 2001;  276 35 494-35 499
• 55 Shapiro S D. Diverse roles of macrophage matrix metalloproteinases in tissue destruction and tumor growth.  Thromb Haemost. 1999;  82 846-849
• 56 Arcavi L, Benowitz N L. Cigarette smoking and infection.  Arch Intern Med. 2004;  164 2206-2216
• 57 Dye J A, Adler K B. Effects of cigarette smoke on epithelial cells of the respiratory tract.  Thorax. 1994;  49 825-834
• 58 Marcy T W, Merrill W W. Cigarette smoking and respiratory tract infection.  Clin Chest Med. 1987;  8 381-391
• 59 Kalra R, Singh S P, Savage S M. et al . Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores.  J Pharmacol Exp Ther. 2000;  293 166-171
• 60 Gerrard J W, Heiner D C, Ko C G. et al . Immunoglobulin levels in smokers and non-smokers.  Ann Allergy. 1980;  44 261-262
• 61 U.S. Department of Health and Human Services .The Health Consequences of Smoking: A Report of the Surgeon General.  Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2004
• 62 Lebowitz M D. Smoking habits and changes in smoking habits as they relate to chronic conditions and respiratory symptoms.  Am J Epidemiol. 1977;  105 534-543
• 63 Walraven G E, Nyan O A, Sande M A van der. et al . Asthma, smoking and chronic cough in rural and urban adult communities in The Gambia.  Clin Exp Allergy. 2001;  31 1679-1685
• 64 Troisi R J, Speizer F E, Rosner B. et al . Cigarette smoking and incidence of chronic bronchitis and asthma in women.  Chest. 1995;  108 1557-1561
• 65 Pilotto L S, Smith B J, Nitschke M. et al . Industry, air quality, cigarette smoke and rates of respiratory illness in Port Adelaide.  Aust N Z J Public Health. 1999;  23 657-660
• 66 Tobacco smoking.  IARC Monogr Eval Carcinog Risk Chem Hum. 1986;  38 35-394
• 67 Doll R, Hill A B. The mortality of doctors in relation to their smoking habits; a preliminary report.  Br Med J. 1954;  1 1451-1455
• 68 Bouchardy C, Benhamou S, Jourenkova N. et al . Metabolic genetic polymorphisms and susceptibility to lung cancer.  Lung Cancer. 2001;  32 109-112
• 69 Doll R, Peto R, Boreham J. et al . Mortality in relation to smoking: 50 years' observations on male British doctors.  Bmj. 2004;  328 1519
• 70 Piipari R, Jaakkola J J, Jaakkola N. et al . Smoking and asthma in adults.  Eur Respir J. 2004;  24 734-739
• 71 Senthilselvan A, Chen Y, Dosman J A. Predictors of asthma and wheezing in adults. Grain farming, sex, and smoking.  Am Rev Respir Dis. 1993;  148 667-670
• 72 Godtfredsen N S, Lange P, Prescott E. et al . Changes in smoking habits and risk of asthma: a longitudinal population based study.  Eur Respir J. 2001;  18 549-554
• 73 Eisner M D, Klein J, Hammond S K. et al . Directly measured second hand smoke exposure and asthma health outcomes.  Thorax. 2005;  60 814-821
• 74 Gilliland F D, Islam T, Berhane K. et al . Regular smoking and asthma incidence in adolescents.  Am J Respir Crit Care Med. 2006;  174 1094-1100
• 75 Genuneit J, Weinmayr G, Radon K. et al . Smoking and the incidence of asthma during adolescence: results of a large cohort study in Germany.  Thorax. 2006;  61 572-578
• 76 Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency.  Acta Paediatr. 1998;  87 1120-1124
• 77 Braman S S. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines.  Chest. 2006;  129 104S-115S
• 78 Andersen A, Berge S R, Engeland A. et al . Exposure to nickel compounds and smoking in relation to incidence of lung and nasal cancer among nickel refinery workers.  Occup Environ Med. 1996;  53 708-713
• 79 Blake G H, Abell T D, Stanley W G. Cigarette smoking and upper respiratory infection among recruits in basic combat training.  Ann Intern Med. 1988;  109 198-202
• 80 Cohen S, Tyrrell D A, Russell M A. et al . Smoking, alcohol consumption, and susceptibility to the common cold.  Am J Public Health. 1993;  83 1277-1283
• 81 Plaschke P P, Janson C, Norrman E. et al . Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking.  Am J Respir Crit Care Med. 2000;  162 920-924
• 82 Nuorti J P, Butler J C, Farley M M. et al . Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team.  N Engl J Med. 2000;  342 681-689
• 83 Almirall J, Gonzalez C A, Balanzo X. et al . Proportion of community-acquired pneumonia cases attributable to tobacco smoking.  Chest. 1999;  116 375-379
• 84 Straus W L, Plouffe J F, File Jr T M. et al . Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group.  Arch Intern Med. 1996;  156 1685-1692
• 85 Kark J D, Lebiush M, Rannon L. Cigarette smoking as a risk factor for epidemic a(h1n1) influenza in young men.  N Engl J Med. 1982;  307 1042-1046
• 86 Buskin S E, Gale J L, Weiss N S. et al . Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990.  Am J Public Health. 1994;  84 1750-1756
• 87 Alcaide J, Altet M N, Plans P. et al . Cigarette smoking as a risk factor for tuberculosis in young adults: a case-control study.  Tuber Lung Dis. 1996;  77 112-116
• 88 Ryu J H, Colby T V, Hartman T E. et al . Smoking-related interstitial lung diseases: a concise review.  Eur Respir J. 2001;  17 122-132
• 89 Katzenstein A L, Myers J L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.  Am J Respir Crit Care Med. 1998;  157 1301-1315
• 90 Coultas D B, Zumwalt R E, Black W C. et al . The epidemiology of interstitial lung diseases.  Am J Respir Crit Care Med. 1994;  150 967-972
• 91 Johnston I D, Prescott R J, Chalmers J C. et al . British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.  Thorax. 1997;  52 38-44
• 92 Marshall R P, Puddicombe A, Cookson W O. et al . Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.  Thorax. 2000;  55 143-146
• 93 Schwartz D A, Merchant R K, Helmers R A. et al . The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis.  Am Rev Respir Dis. 1991;  144 504-506
• 94 Baumgartner K B, Samet J M, Stidley C A. et al . Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1997;  155 242-248
• 95 Hubbard R, Venn A, Lewis S. et al . Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.  Am J Respir Crit Care Med. 2000;  161 5-8
• 96 Hartman T E, Primack S L, Kang E Y. et al . Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT.  Chest. 1996;  110 378-382
• 97 Yousem S A, Colby T V, Gaensler E A. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia.  Mayo Clin Proc. 1989;  64 1373-1380
• 98 Niewoehner D E, Kleinerman J, Rice D B. Pathologic changes in the peripheral airways of young cigarette smokers.  N Engl J Med. 1974;  291 755-758
• 99 Myers J L, Veal C C F, Shin M S. et al . Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases.  Am Rev Respir Dis. 1987;  135 880-884
• 100 Favara B E, Feller A C, Pauli M. et al . Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.  Med Pediatr Oncol. 1997;  29 157-166
• 101 Hance A J, Basset F, Saumon G. et al . Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis.  Ann N Y Acad Sci. 1986;  465 643-656
• 102 Casolaro M A, Bernaudin J F, Saltini C. et al . Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking.  Am Rev Respir Dis. 1988;  137 406-411
• 103 Westedt M L, Hazes J M, Breedveld F C. et al . Cigarette smoking and pulmonary diffusion defects in rheumatoid arthritis.  Rheumatol Int. 1998;  18 1-4
• 104 Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis.  J Rheumatol. 2000;  27 630-637
• 105 Banks J, Banks C, Cheong B. et al . An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis.  Q J Med. 1992;  85 795-806
• 106 Hyland R H, Gordon D A, Broder I. et al . A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis.  J Rheumatol. 1983;  10 395-405
• 107 Merkel F, Pullig O, Marx M. et al . Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases.  Nephrol Dial Transplant. 1994;  9 372-376
• 108 Kelly P T, Haponik E F. Goodpasture syndrome: molecular and clinical advances.  Medicine (Baltimore). 1994;  73 171-185
• 109 Pauwels R A, Rabe K F. Burden and clinical features of chronic obstructive pulmonary disease (COPD).  Lancet. 2004;  364 613-620
• 110 Murray C J, Lopez A D. Alternative projections of mortality and disability by cause 1990 - 2020: Global Burden of Disease Study.  Lancet. 1997;  349 1498-1504
• 111 Behr J, Nowak D. Tobacco smoke and respiratory disease.  In: d'Amato G, Holgate S (eds). European Respiratory Monograph (7) The impact of air pollution on respiratory health.  ERS. 2002;  21 161-179
• 112 European Commission .Tobacco or Health in the European Union - past, present and future. The ASPECT Consortium. Luxembourg: Office for Official Publications of the European Communities 2004
• 113 Shahab L, Jarvis M J, Britton J R. et al . Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample.  Thorax. 2006;  61 1043-1047
• 114 Criée C P, Novak D. Einsparpotential durch Prävention bei COPD. In: Schauder P, Berthold H, Eckel H, Ollenschläger G (eds). Zukunft sichern: Senkung der Zahl chronisch Kranker, Verwirklichung einer realistischen Utopie. Köln: Deutscher Ärzteverlag 2006: 205-208
• 115 de Marco R, Accordini S, Cerveri I. et al . An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages.  Thorax. 2004;  59 120-125
• 116 Chapman K R, Mannino D M, Soriano J B. et al . Epidemiology and costs of chronic obstructive pulmonary disease.  Eur Respir J. 2006;  27 188-207
• 117 Nowak D, Berger K, Lippert B. et al . Epidemiology and health economics of COPD across Europe: a critical analysis.  Treat Respir Med. 2005;  4 381-395
• 118 Buist A S, McBurnie M A, Vollmer W M. et al . International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.  Lancet. 2007;  370 741-750
• 119 Burney P. The pharmacoepidemiology of COPD: Recent advances and methodological discussion.  Eur Respir J. 2003;  22 1S-44S
• 120 Lundback B, Lindberg A, Lindstrom M. et al . Not 15 but 50 % of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies.  Respir Med. 2003;  97 115-122
• 121 Wedzicha J A, Donaldson G C. Exacerbations of chronic obstructive pulmonary disease.  Respir Care. 2003;  48 1204-1213; discussion 1213 - 1205
• 122 Lundback B, Gulsvik A, Albers M. et al . Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly.  Eur Respir J Suppl. 2003;  40 3s-9s
• 123 Lokke A, Lange P, Scharling H. et al . Developing COPD: a 25 year follow up study of the general population.  Thorax. 2006;  61 935-939
• 124 Prescott E, Bjerg A M, Andersen P K. et al . Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study.  Eur Respir J. 1997;  10 822-827
• 125 Xu X, Li B, Wang L. Gender difference in smoking effects on adult pulmonary function.  Eur Respir J. 1994;  7 477-483
• 126 Chapman K R. Chronic obstructive pulmonary disease: are women more susceptible than men?.  Clinics in Chest Medicine. 2004;  25 331-341
• 127 Cookson W O. State of the art. Genetics and genomics of chronic obstructive pulmonary disease.  Proc Am Thorac Soc. 2006;  3 473-475
• 128 Rennard S I, Vestbo J. COPD: the dangerous underestimate of 15 %.  Lancet. 2006;  367 1216-1219
• 129 Falk G A, Briscoe W A. Alpha-1-antitrypsin deficiency in chronic obstructive pulmonary disease.  Ann Intern Med. 1970;  72 427-429
• 130 Wouters E F. Chronic obstructive pulmonary disease. 5: systemic effects of COPD.  Thorax. 2002;  57 1067-1070
• 131 Reid M B. COPD as a muscle disease.  Am J Respir Crit Care Med. 2001;  164 1101-1102
• 132 Anthonisen N R, Skeans M A, Wise R A. et al . The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.  Ann Intern Med. 2005;  142 233-239
• 133 Andreas S, Anker S D, Scanlon P D. et al . Neurohumoral activation as a link to systemic manifestation of chronic lung disease.  Chest. 2005;  128 3618-3624
• 134 Yanbaeva D G, Dentener M A, Creutzberg E C. et al . Systemic Effects of Smoking.  Chest. 2007;  131 1557-1566
• 135 Cerveri I, Accordini S, Corsico A. et al . Chronic cough and phlegm in young adults.  Eur Respir J. 2003;  22 413-417
• 136 Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV₁ decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.  Am J Respir Crit Care Med. 1996;  153 1530-1535
• 137 Kerstjens H A, Rijcken B, Schouten J P. et al . Decline of FEV₁ by age and smoking status: facts, figures, and fallacies.  Thorax. 1997;  52 820-827
• 138 Fletcher C, Peto R. The natural history of chronic airflow obstruction.  Br Med J. 1977;  1 1645-1648
• 139 Gold D R, Wang X, Wypij D. et al . Effects of cigarette smoking on lung function in adolescent boys and girls.  N Engl J Med. 1996;  335 931-937
• 140 Sherrill D L, Lebowitz M D, Knudson R J. et al . Smoking and symptom effects on the curves of lung function growth and decline.  Am Rev Respir Dis. 1991;  144 17-22
• 141 Xu X, Weiss S T, Rijcken B. et al . Smoking, changes in smoking habits, and rate of decline in FEV₁: new insight into gender differences.  Eur Respir J. 1994;  7 1056-1061
• 142 Anthonisen N R. Lung Health Study.  Am Rev Respir Dis. 1989;  140 871-872
• 143 Anthonisen N R, Connett J E, Enright P L. et al . Hospitalizations and mortality in the Lung Health Study.  Am J Respir Crit Care Med. 2002;  166 333-339
• 144 Anthonisen N R, Lindgren P G, Tashkin D P. et al . Bronchodilator response in the lung health study over 11 yrs.  Eur Respir J. 2005;  26 45-51
• 145 Scanlon P D, Connett J E, Waller L A. et al . Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.  Am J Respir Crit Care Med. 2000;  161 381-390
• 146 Viegi G, Paoletti P, Carrozzi L. et al . CO diffusing capacity in a general population sample: relationships with cigarette smoking and airflow obstruction.  Respiration. 1993;  60 155-161
• 147 Viegi G, Sherrill D L, Carrozzi L. et al . An 8-year follow-up of carbon monoxide diffusing capacity in a general population sample of northern italy.  Chest. 2001;  120 74-80
• 148 Verbanck S, Schuermans D, Paiva M. et al . Small airway function improvement after smoking cessation in smokers without airway obstruction.  Am J Respir Crit Care Med. 2006;  174 853-857
• 149 Willemse B W, Postma D S, Timens W. et al . The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.  Eur Respir J. 2004;  23 464-476
• 150 Willemse B W, ten Hacken N H, Rutgers B. et al . Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD.  Eur Respir J. 2004;  24 391-396
• 151 Magnussen H, Goeckenjan G, Kohler D. et al . Guidelines to long-term oxygen therapy.  Pneumologie. 2001;  55 454-464
• 152 Lacasse Y, LaForge J, Maltais F. Got a match? Home oxygen therapy in current smokers.  Thorax. 2006;  61 374-375
• 153 Heidrich J, Wellmann J, Heuschmann P U. et al . Mortality and morbidity from coronary heart disease attributable to passive smoking.  Eur Heart J. 2007;  28 2498-2502
• 154 European Respiratory Society .Lifting the smokescreen.  Brussels: European Respiratory Society 2006
• 155 Jaakkola M S, Jaakkola J J. Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention.  Eur Respir J. 2006;  28 397-408
• 156 Lam T H, Ho L M, Hedley A J. et al . Secondhand smoke and respiratory ill health in current smokers.  Tob Control. 2005;  14 307-314
• 157 Raupach T, Radon K, Nowak D. et al . Passive Smoking - Health Consequences and Effects of Exposure Prevention.  Pneumologie. 2008;  62 44-50
• 158 Jimenez-Ruiz C A, Masa F, Miravitlles M. et al . Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD.  Chest. 2001;  119 1365-1370
• 159 Jimenez-Ruiz C, Miravitlles M, Sobradillo V. et al . Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease?.  Nicotine Tob Res. 2004;  6 649-653
• 160 Hertzen L von, Reunanen A, Impivaara O. et al . Airway obstruction in relation to symptoms in chronic respiratory disease - a nationally representative population study.  Respiratory Medicine. 2000;  94 356-363
• 161 Medici T C, Unger S, Ruegger M. Smoking pattern of smokers with and without tobacco-smoke-related lung diseases.  Am Rev Respir Dis. 1985;  131 385-388
• 162 Killen J, Fortmann S, Kraemer H. et al . Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation.  J Consult Clin Psychol. 1992;  60 797-801
• 163 Clark K D, Wardrobe-Wong N, Elliott J J. et al . Cigarette smoke inhalation and lung damage in smoking volunteers.  Eur Respir J. 1998;  12 395-399
• 164 Wagena E J, Huibers M J, Schayck C P van. Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression.  Thorax. 2001;  56 587-588
• 165 Manen J G van, Bindels P JE, Dekker F W. et al . Risk of depression in patients with chronic obstructive pulmonary disease and its determinants.  Thorax. 2002;  57 412-416
• 166 Wagena E J, Meer R M van der, Ostelo R J. et al . The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review.  Respir Med. 2004;  98 805-815
• 167 Yohannes A M, Roomi J, Baldwin R C. et al . Depression in elderly outpatients with disabling chronic obstructive pulmonary disease.  Age and Ageing. 1998;  27 155-160
• 168 Dudley D, Glaser E, Jorgenson B. et al . Psychosocial concomitants to rehabilitation in chronic obstructive pulmonary disease. 3. Dealing with psychiatric disease (as distinguished from psychosocial or psychophysiologic problems).  Chest. 1980;  77 667
• 169 Isoaho R, Puolijoki H, Huhti E. et al . Chronic obstructive pulmonary disease and self-maintaining functions in the elderly - a population-based study.  Scand J Prim Health Care. 1995;  13 122-127
• 170 O'Neill E. Illness representations and coping of women with chronic obstructive pulmonary disease: a pilot study.  Heart Lung. 2002;  31 295-302
• 171 DiMarco F, Verga M, Reggente M. et al . Anxiety and depression in COPD patients: The roles of gender and disease severity.  Respir Med. 2006;  100 1767-1774
• 172 Ng T P, Niti M, Tan W C. et al . Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life.  Arch Intern Med. 2007;  167 60-67
• 173 Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004: CD000031
• 174 Breslau N, Johnson E O, Hiripi E. et al . Nicotine Dependence in the United States - Prevalence, Trends, and Smoking Persistence.  Arch Gen Psychiatry. 2001;  58 810-816
• 175 Glassman A H, Covey L S, Stetner F. et al . Smoking cessation and the course of major depression: a follow-up study.  Lancet. 2001;  357 1929-1932
• 176 Breslau N, Peterson E L, Schultz L R. et al . Major Depression and Stages of Smoking.  A Longitudinal Investigation. 1998;  55 161-166
• 177 Dierker L, Avenevoli S, Stolar M. et al . Smoking and depression: an examination of mechanisms of comorbidity.  Am J Psychiatry. 2002;  159 947-953
• 178 Covey L, Glassman A, Stetner F. Cigarette smoking and major depression.  J Addict Dis. 1998;  17 35-46
• 179 Wilhelm K, Arnold K, Niven H. et al . Grey lungs and blue moods: smoking cessation in the context of lifetime depression history.  Aust N Z J Psychiatry. 2004;  38 896-905
• 180 Breslau N. Psychiatric comorbidity of smoking and nicotine dependence.  Behav Genet. 1995;  25 95-101
• 181 John U, Meyer C, Rumpf H J. et al . Smoking, nicotine dependence and psychiatric comorbidity - a population-based study including smoking cessation after three years.  Drug Alcohol Depend. 2004;  76 287-295
• 182 Haug N A, Heinberg L J, Guarda A S. Cigarette smoking and its relationship to other substance use among eating disordered inpatients.  Eat Weight Disord. 2001;  6 130-139
• 183 Kordon A, Kahl K G. Attention-deficit/hyperactivity disorder (ADHS) in adulthood.  Psychother Psychosom Med Psychol. 2004;  54 124-136
• 184 Anthonisen N R, Connett J E, Murray R P. Smoking and lung function of Lung Health Study participants after 11 years.  Am J Respir Crit Care Med. 2002;  166 675-679
• 185 Heatherton T F, Kozlowski L T, Frecker R C. et al . The Fagerstrom-Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire.  Br J Addict. 1991;  86 1119-1127
• 186 Anda R F, Williamson D F, Escobedo L G. et al . Depression and the dynamics of smoking. A national perspective.  Jama. 1990;  264 1541-1545
• 187 Killen J D, Fortmann S P, Kraemer H C. et al . Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse.  J Consult Clin Psychol. 1996;  64 1060-1067
• 188 Herrmann C, Buss U. Vorstellung und Validierung einer deutschen Version der „Hospital Anxiety and Depression Scale” (HAD-Skala); ein Fragebogen zur Erfassung des psychischen Befindens bei Patienten mit körperlichen Beschwerden.  Diagnostica. 1994;  40 143-154
• 189 Löwe B. PHQ-D - Gesundheitsfragebogen für Patienten. In: Schumacher J, Strauss B (eds). Klinische Interviews und Ratingskalen Göttingen: Hogrefe 2004: 321-327
• 190 Riemann K, Gerber U. Standardisierung von Fragestellungen zum Rauchen: ein Beitrag zur Qualitätssicherung in der Präventionsforschung. 4 ed: BZgA. Köln: Bundeszentrale für gesundheitliche Aufklärung 2000
• 191 Hilberink S R, Jacobs J E, Schlosser M. et al . Characteristics of patients with COPD in three motivational stages related to smoking cessation.  Patient Educ Couns. 2006;  61 449-457
• 192 Bize R, Burnand B, Mueller Y. et al .Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2005: CD004705
• 193 West R, Hajek P, Stead L. et al . Outcome criteria in smoking cessation trials: proposal for a common standard.  Addiction. 2005;  100 299-303
• 194 Brandt C J, Ellegaard H, Joensen M. et al . Effect of diagnosis of “smoker's lung”. RYLUNG Group.  Lancet. 1997;  349 253
• 195 Humerfelt S, Eide G E, Kvåle G. et al . Effectiveness of postal smoking cessation advice: a randomized controlled trial in young men with reduced FEV₁ and asbestos exposure.  Eur Respir J. 1998;  11 284-290
• 196 Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not.  Br J Gen Pract. 2002;  52 132-134
• 197 Bednarek M, Gorecka D, Wielgomas J. et al . Smokers with airway obstruction are more likely to quit smoking.  Thorax. 2006;  61 869-73
• 198 Gorecka D, Bednarek M, Nowinski A. et al . Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate.  Chest. 2003;  123 1916-1923
• 199 Townsend C O, Clark M M, Jett J R. et al . Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening.  Cancer. 2005;  103 2154-2162
• 200 A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report.  Jama. 2000;  283 3244-3254
• 201 Soria R, Legido A, Escolano C. et al . A randomised controlled trial of motivational interviewing for smoking cessation.  Br J Gen Pract. 2006;  56 768-774
• 202 Miller W R. Motivational interviewing: research, practice, and puzzles.  Addict Behav. 1996;  21 835-842
• 203 O'Hara P, Grill J, Rigdon M A. et al . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group.  Prev Med. 1993;  22 304-315
• 204 Anthonisen N R, Connett J E, Kiley J P. et al . Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV₁. The Lung Health Study.  Jama. 1994;  272 1497-1505
• 205 Godtfredsen N S, Vestbo J, Osler M. et al . Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study.  Thorax. 2002;  57 967-972
• 206 Kanner R E, Anthonisen N R, Connett J E. Lower respiratory illnesses promote FEV₁ decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.  Am J Respir Crit Care Med. 2001;  164 358-364
• 207 Jo Y H, Talmage D A, Role L W. Nicotinic receptor-mediated effects on appetite and food intake.  J Neurobiol. 2002;  53 618-632
• 208 Williamson D F, Madans J, Anda R F. et al . Smoking cessation and severity of weight gain in a national cohort.  N Engl J Med. 1991;  324 739-745
• 209 Flegal K M, Troiano R P, Pamuk E R. et al . The influence of smoking cessation on the prevalence of overweight in the United States.  N Engl J Med. 1995;  333 1165-1170
• 210 Carroll M E, Meisch R A. Increased drug-reinforced behaviour due to food deprivation. In: Thompson T, Dews PB, JE B (eds). Advances in Behavioural Pharmacology. Orlando: Academic Press Inc 1984: 47-88
• 211 Swan G E, Carmelli D. Characteristics associated with excessive weight gain after smoking cessation in men.  Am J Public Health. 1995;  85 73-77
• 212 Pomerleau C S, Zucker A N, Stewart A J. Characterizing concerns about post-cessation weight gain: results from a national survey of women smokers.  Nicotine Tob Res. 2001;  3 51-60
• 213 Hughes J R, Gust S W, Skoog K. et al . Symptoms of tobacco withdrawal. A replication and extension.  Arch Gen Psychiatry. 1991;  48 52-59
• 214 Pisinger C, Jorgensen T. Weight concerns and smoking in a general population: the Inter99 study.  Prev Med. 2007;  44 283-289
• 215 Nordstrom B L, Kinnunen T, Utman C H. et al . Long-term effects of nicotine gum on weight gain after smoking cessation.  Nicotine Tob Res. 1999;  1 259-268
• 216 Hays J T, Hurt R D, Rigotti N A. et al . Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.  Ann Intern Med. 2001;  135 423-433
• 217 Marcus B H, Albrecht A E, King T K. et al . The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial.  Arch Intern Med. 1999;  159 1229-1234
• 218 Kadowaki T, Watanabe M, Okayama A. et al . Continuation of smoking cessation and following weight change after intervention in a healthy population with high smoking prevalence.  J Occup Health. 2006;  48 402-406
• 219 Lange P, Groth S, Nyboe G J. et al . Effects of smoking and changes in smoking habits on the decline of FEV₁.  Eur Respir J. 1989;  2 811-816
• 220 Simmons M S, Connett J E, Nides M A. et al . Smoking reduction and the rate of decline in FEV₁: results from the Lung Health Study.  Eur Respir J. 2005;  25 1011-1017
• 221 Sherrill D L, Enright P, Cline M. et al . Rates of decline in lung function among subjects who restart cigarette smoking.  Chest. 1996;  109 1001-1005
• 222 Bolliger C T, Zellweger J P, Danielsson T. et al . Influence of long-term smoking reduction on health risk markers and quality of life.  Nicotine Tob Res. 2002;  4 433-439
• 223 Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption.  Tobacco Control. 2006;  15 472-480
• 224 Raupach T, Shahab L, Neubert K. et al .Implementing a hospital-based smoking cessation programme: Evidence for a learning effect. Patient Educ Couns 2008 (in press)
• 225 Wagena E J, Zeegers M P, Schayck C P van. et al . Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.  Drug Saf. 2003;  26 381-403
• 226 van der Meer R M, Wagena E J, Ostelo R W. et al .Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003: CD002999
• 227 Tashkin D, Kanner R, Bailey W. et al . Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.  Lancet. 2001;  357 1571-1575
• 228 Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support.  Chest. 2006;  130 334-342
• 229 Wagena E J, Knipschild P G, Huibers M JH. et al . Efficacy of Bupropion and Nortriptyline for Smoking Cessation Among People at Risk for or With Chronic Obstructive Pulmonary Disease.  Arch Intern Med. 2005;  165 2286-2292
• 230 Hering T, Bölcskei P, Storz C. et al .Strukturierte Raucherberatung und Tabakentwöhnung - Tabakentwöhnung in der Praxis-Sprechstunde (das Tabakentwöhnungskonzept des Bundesverbandes der Pneumologen in Deutschland - BDP). In: Vorträge der 5 Deutschen Nikotin Konferenz: ed. K. Haustein. Erfurt: Deutsche Gesellschaft für Nikotinforschung 2002: 121-124
• 231 Moher M, Hey K, Lancaster T. Workplace interventions for smoking cessation. Cochrane Database Syst Rev 2005: CD003440
• 232 Twardella D, Brenner H. Effects of practitioner education, practitioner payment and reimbursement of patients' drug costs on smoking cessation in primary care: a cluster randomised trial.  Tobacco Control. 2007;  16 15-21
• 233 Silagy C, Lancaster T, Stead L. et al .Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004: CD000146
• 234 Organization WH .Regulation of Nicotine Replacement Therapies: An Expert Consensus. Copenhagen: Regional Office for Europe 2001
• 235 Gonzales D, Rennard S I, Nides M. et al . Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.  Jama. 2006;  296 47-55
• 236 Nides M, Oncken C, Gonzales D. et al . Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.  Arch Intern Med. 2006;  166 1561-1568
• 237 Oncken C, Gonzales D, Nides M. et al . Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.  Arch Intern Med. 2006;  166 1571-1577
• 238 Tonstad S, Tonnesen P, Hajek P. et al . Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.  Jama. 2006;  296 64-71
• 239 Jorenby D E, Hays J T, Rigotti N A. et al . Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.  Jama. 2006;  296 56-63
• 240 Cahill K, Stead L F, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007: CD006103
• 241 Gourlay S G, Stead L F, Benowitz N L. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004: CD000058
• 242 Bundeszentrale für gesundheitliche Aufklärung (BzgA) .Kriterien guter Praxis in der Gesundheitsförderung bei sozial Benachteiligten. Köln 2005
• 243 Morgan W J. Maternal smoking and infant lung function. Further evidence for an in utero effect.  Am J Respir Crit Care Med. 1998;  158 689-690
• 244 Ruff L K, Volmer T, Nowak D. et al . The economic impact of smoking in Germany.  Eur Respir J. 2000;  16 385-390
• 245 Parrott S, Godfrey C, Raw M. Costs of employee smoking in the workplace in Scotland.  Tob Control. 2000;  9 187-192
• 246 Murray R P, Connett J E, Rand C S. et al . Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years.  Prev Med. 2002;  35 314-319
• 247 Raupach T, Shahab L, Neubert K. et al . Implementing a hospital-based smoking cessation programme: Evidence for a learning effect.  Patient Educ Couns. 2008;  70 199-204
• 248 Tengs T O, Adams M E, Pliskin J S. et al . Five-hundred life-saving interventions and their cost-effectiveness.  Risk Anal. 1995;  15 369-390
• 249 Thomas R, Perera R. School-based programmes for preventing smoking.  Cochrane Database Syst Rev. 2006;  3 CD001293
• 250 Secker-Walker R H, Gnich W, Platt S. et al .Community interventions for reducing smoking among adults. Cochrane Database Syst Rev 2002: CD001745
• 251 Stead L F, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005: CD001007